MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications

American Journal of Respiratory Cell and Molecular Biology

Volumn 42, Issue 3, 2010, Pages 312-319

  Busacca, Sara ^a   Germano, Serena ^a   De Cecco, Loris ^b,c   Rinaldi, Maurizio ^a   Comoglio, Federico ^a   Favero, Francesco ^d   Murer, Bruno ^e   Mutti, Luciano ^f   Pierotti, Marco ^b,c   Gaudino, Giovanni ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d Laboratory of Cancer Genomics   (Italy)

^e Dell'Angelo Hospital   (Italy)

^f Local Health Unit 11   (Italy)

Author keywords

Human malignant mesothelioma; Microarray; MicroRNAs; Real time quantitative RT PCR; Survival

Indexed keywords

BIOLOGICAL MARKER; MICRORNA;

ALGORITHM; ARTICLE; CANCER CELL; CANCER SURVIVAL; CARCINOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE EXPRESSION; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALIGNANT MESOTHELIOMA; MATHEMATICAL COMPUTING; MESOTHELIUM CELL; PREDICTIVE VALIDITY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CELL LINE, TUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MESOTHELIOMA; MICRORNAS; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 77249135944     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2009-0060OC     Document Type: Article

References (37)

1. Pass HI, Vogelzang N, Hahn S, Carbone M. Malignant pleural mesothelioma. Curr Probl Cancer 2004;28:93-174.
2. Carbone M, Emri S, Dogan AU, Steele I, Tuncer M, Pass HI, Baris YI. A mesothelioma epidemic in cappadocia: scientific developments and unexpected social outcomes. Nat Rev Cancer 2007;7:147-154.
3. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, Bubici C, Mossman BT, Pass HI, Testa JR, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci USA 2006;103:10397- 10402.
4. Sartore-Bianchi A, Gasparri F, Galvani A, Nici L, Darnowski JW, Barbone D, Fennell DA, Gaudino G, Porta C, Mutti L. Bortezomib inhibits nuclear factor-kappaB dependent survival and has potent in vivo activity in mesothelioma. Clin Cancer Res 2007;13:5942-5951.
5. Cacciotti P, Barbone D, Porta C, Altomare DA, Testa JR, Mutti L, Gaudino G. Sv40-dependent Akt activity drives mesothelial cell transformation after asbestos exposure. Cancer Res 2005;65:5256-5262.
6. Bertino P, Marconi A, Palumbo L, Bruni BM, Barbone D, Germano S, Dogan AU, Tassi GF, Porta C, Mutti L, et al. Erionite and asbestos differently cause transformation of human mesothelial cells. Int J Cancer 2007;121:12-20.
7. Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-1603.
8. Miska EA. How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 2005;15:563-568.
9. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-838.
10. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et al. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 2006;103:2257-2261.
11. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008;68:26-33.
12. Orengo AM, Spoletini L, Procopio A, Favoni RE, De Cupis A, Ardizzoni A, Castagneto B, Ribotta M, Betta PG, Ferrini S, et al. Establishment of four new mesothelioma cell lines: characterization by ultrastructural and immunophenotypic analysis. Eur Respir J 1999; 13:527-534.
13. Smythe WR, Kaiser LR, Hwang HC, Amin KM, Pilewski JM, Eck SJ, Wilson JM, Albelda SM. Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 1994;57:1395-1401.
14. Dickson MA, Hahn WC, Ino Y, Ronfard V, Wu JY, Weinberg RA, Louis DN, Li FP, Rheinwald JG. Human keratinocytes that express hTERT and also bypass a p16(ink4a)-enforced mechanism that limits life span become immortal yet retain normal growth and differentiation characteristics. Mol Cell Biol 2000;20:1436-1447.
15. Pietruska JR, Kane AB. Sv40 oncoproteins enhance asbestos-induced DNA double-strand breaks and abrogate senescence in murine mesothelial cells. Cancer Res 2007;67:3637-3645.
16. De Cecco L, Marchionni L, Gariboldi M, Reid JF, Lagonigro MS, Caramuta S, Ferrario C, Bussani E, Mezzanzanica D, Turatti F, et al. Gene expression profiling of advanced ovarian cancer: characterization of a molecular signature involving fibroblast growth factor 2. Oncogene 2004;23:8171-8183.
17. Rascoe PA, Cao X, Daniel JC, Miller SD, Smythe WR. Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma. J Thorac Cardiovasc Surg 2005;130:393-400.
18. Gentleman RMM, Huber W. Gene set enrichment analysis. In: Hahne F, Gentleman R, Falcon S, editors. Bioconductor case studies. New York: Springer; 2008. pp. 193-205.
19. Lall S, Grun D, Krek A, Chen K, Wang YL, Dewey CN, Sood P, Colombo T, Bray N, Macmenamin P, et al. A genome-wide map of conserved microRNA targets in c. Elegans. Curr Biol 2006;16:460-471.
20. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell 2003;115:787-798.
21. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. Human microRNA targets. PLoS Biol 2004;2:e363.
22. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z, Hatzigeorgiou A. A combined computational-experimental approach predicts human microRNA targets. Genes Dev 2004;18:1165-1178.
23. Marrogi A, Pass HI, Khan M, Metheny-Barlow LJ, Harris CC, Gerwin BI. Human mesothelioma samples overexpress both cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (NOS2): in vitro antiproliferative effects of a COX-2 inhibitor. Cancer Res 2000;60: 3696-3700.
24. Fennell DA, Rudd RM. Defective core-apoptosis signalling in diffuse malignant pleural mesothelioma: opportunities for effective drug development. Lancet Oncol 2004;5:354-362.
25. Michael MZ, O'Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003;1:882-891.
26. Fennell DA, Parmar A, Shamash J, Evans MT, Sheaff MT, Sylvester R, Dhaliwal K, Gower N, Steele J, Rudd R. Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 2005;23:184-189.
27. Mendell JT. Miriad roles for the miR-17-92 cluster in development and disease. Cell 2008;133:217-222.
28. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M, et al. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006;5:29.
29. Meng F, Henson R, Wehbe-Janek H, Smith H, Ueno Y, Patel T. The microRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem 2007; 282:8256-8264.
30. Cheng C, Li LM. Inferring microRNA activities by combining gene expression with microRNA target prediction. PLoS ONE April 23, 2008;3(4):e1989.
31. Baldi A, Santini D, Vasaturo F, Santini M, Vicidomini G, Di Marino MP, Esposito V, Groeger AM, Liuzzi G, Vincenzi B, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax 2004;59:428-433.
32. Bard MP, Hegmans JP, Hemmes A, Luider TM, Willemsen R, Severijnen LA, van Meerbeeck JP, Burgers SA, Hoogsteden HC, Lambrecht BN. Proteomic analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004;31:114-121.
33. Cacciotti P, Libener R, Betta P, Martini F, Porta C, Procopio A, Strizzi L, Penengo L, Tognon M, Mutti L, et al. Sv40 replication in human mesothelial cells induces HGF/MET receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma. Proc Natl Acad Sci USA 2001;98:12032-12037.
34. Christensen BC, Godleski JJ, Marsit CJ, Houseman EA, Lopez-Fagundo CY, Longacker JL, Bueno R, Sugarbaker DJ, Nelson HH, Kelsey KT. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008;29: 1555-1559.
35. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J, Bartel DP, Linsley PS, Johnson JM. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005;433:769-773.
36. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R, Donfrancesco A, Federici V, Giacomini P, et al. AntagomiR-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and bim. PLoS One May 21, 2008;3:e2236.
37. Yu Z, Wang C, Wang M, Li Z, Casimiro MC, Liu M,Wu K, Whittle J, Ju X, Hyslop T, et al. A cyclin d1/microRNA 17/20 regulatory feedback loop in control of breast cancer cell proliferation. J Cell Biol 2008;182: 509-517.